Skip to main content

Liposomal Bupivacaine (Exparel)

Liposomal bupivacaine is a multivesicular-liposomal formulation of bupivacaine designed to release drug over up to 72 hours from a single injection — theoretically an ideal ERAS adjunct for wound infiltration and peripheral / fascial-plane blocks. The evidence has not supported the theory. Across 76+ RCTs reviewed in the definitive Anesthesiology 2021 analysis, only 11% (4/36) comparing surgical infiltration of liposomal bupivacaine (LB) to standard bupivacaine HCl showed a clinically relevant benefit, and studies with financial conflicts of interest were 14× more likely to report positive pain outcomes (OR 14.31; p = 0.0001).[1][2] The CLEVELAND 2025 three-arm RCT brought the debate to its logical conclusion — single-shot pre-incision TAP blocks with LB, plain bupivacaine, or saline placebo all produced identical opioid consumption and pain scores.[9]

This article is the drug-class pharmacology hub — formulation, preparation rules (they matter), FDA-approved doses and indications, comparison evidence vs standard bupivacaine in infiltration, TAP, and urologic contexts, and cost. For the broader local-anesthetic class (lidocaine, ropivacaine, standard bupivacaine across 12 urologic use cases) see Local anesthetics. For ERAS workflow context see ERAS.

Pharmacology​

Formulation​

Multivesicular liposomes — microscopic honeycomb-like lipid-based particles with multiple aqueous chambers separated by lipid bilayers. Upon injection, liposomes gradually erode and release bupivacaine over an extended period. Like all amide-type local anesthetics, released bupivacaine blocks sodium channels → inhibited nerve impulse generation and conduction.[3][4]

Pharmacokinetics​

ParameterDetail
AbsorptionDepends on total dose, route, vascularity. Systemic plasma levels observed for 96 h after local infiltration, 120 h after interscalene block, 168 h after sciatic / adductor-canal block[4]
Protein binding95% (plasma)
DistributionHighly perfused organs; crosses placenta (F/M ratio 0.2–0.4)
MetabolismHepatic glucuronic-acid conjugation — caution in hepatic disease
Systemic levelsDo not correlate with local efficacy

FDA-Approved Indications & Dosing​

IndicationDoseVolumeAge
Local infiltration (adults)Up to 266 mg (20 mL of 1.3%)Dilute with NS or LR up to 1:14 (final concentration ≥ 0.89 mg/mL)≥ 18 yr
Local infiltration (pediatric)4 mg/kg (max 266 mg)Same dilution rules6–17 yr
Interscalene brachial plexus block133 mg (10 mL)10 mLAdults
Sciatic nerve block (popliteal fossa)133 mg (10 mL)10 mLAdults
Adductor canal block133 mg + 50 mg bupivacaine HCl 0.5% (10 mL each = 20 mL total)20 mLAdults

Source: FDA label.[4]

Preparation and Drug-Interaction Rules — Critical and Unique​

Preparation rules specific to liposomal bupivacaine

These rules are different from standard bupivacaine and are the most common source of drug-waste and lost sustained-release effect.

  • Do NOT admix with other local anesthetics (except bupivacaine HCl for adductor canal block). Lidocaine and other non-bupivacaine locals cause immediate release of encapsulated bupivacaine → the sustained-release mechanism is destroyed.[4]
  • Lidocaine may be administered ≥ 20 min BEFORE liposomal bupivacaine at the same site. Other non-bupivacaine locals — no data supporting pre-administration.
  • Avoid additional local anesthetics for 96 h after liposomal bupivacaine at the same site — an unusual constraint that limits multimodal pain-management flexibility.
  • Do NOT dilute with water or hypotonic agents — disrupts liposomal particles. Use 0.9% preservative-free NS or LR only.
  • Use a 25-gauge or larger needle to preserve particle integrity.
  • Invert vial multiple times to re-suspend particles immediately before withdrawal.
  • Use diluted product within 4 h of preparation.
  • Methemoglobinemia risk with concurrent nitrates/nitrites, other local anesthetics, dapsone, sulfonamides, antimalarials, or acetaminophen.[4]

Evidence — Infiltration vs Standard Bupivacaine​

The most-studied comparison and the most consistently negative signal in local-anesthesia literature.

SourceFinding
Ilfeld 2021 Anesthesiology comprehensive review of 76 RCTsOnly 11% (4/36) of surgical-infiltration RCTs showed clinically relevant benefit vs standard bupivacaine. 92% (11/12) of trials showed peripheral nerve block with standard bupivacaine is superior to infiltrated LB. Among low-risk-of-bias trials, only 14% (4/28) reported significant differences — vs 84% (16/19) of high-risk-of-bias trials[1]
Ji 2021 J Surg Res SR of 63 RCTs, n = 6,770LB did not demonstrate significant pain relief in 74.6% of RCTs; no opioid reduction in 85.7% overall (83.3% vs standard bupivacaine). Financial COI association: OR 14.31 for pain (p = 0.0001), OR 12.35 for opioid reduction (p = 0.024). 47.5% of 265 registered RCTs withdrawn / terminated / suspended / unpublished — substantial publication bias[2]
Dinges 2021 RAPM meta + trial sequential analysis, 23 RCTs, n = 1,867Pain ↓ 0.37 points on 10-point scale at 24 h (p < 0.05) — statistically significant, below the 1-point MCID. 15% morphine-equivalent ↓ at 24 h. No significant pain difference at 72 h[5]
Hamilton 2017 CochraneLower cumulative 0–72 h pain vs placebo (very-low-certainty); no difference vs standard bupivacaine (very-low-certainty)[6]
Sandhu 2021 JAMA Network Open RCT, n = 280, truncal incisionsNo benefit over standard bupivacaine[7]
Saad Sayed 2025 meta (8 RCTs, n = 810, abdominal surgery)No significant pain score difference POD 0, 1, 2, 3. No morphine reduction any day. LB not superior to standard bupivacaine in the surgical plane for abdominal procedures[8]

Bottom line — infiltration: the statistically significant 0.37-point pain-score reduction at 24 h falls below the MCID, the signal fades by 72 h, and studies with industry conflict are 14× more likely to report positive outcomes.

Evidence — TAP Blocks​

Particularly relevant for the reconstructive urologist — TAP blocks are a standard ERAS adjunct for major abdominopelvic surgery.

CLEVELAND 2025 — the decisive trial[9]​

Triple-blinded 3-arm RCT (n = 261) comparing LB TAP vs plain bupivacaine TAP vs saline placebo TAP for major abdominal surgery:

  • Opioid consumption 0–24 h: 26 MME (LB) vs 33 MME (plain bupivacaine) vs 31 MME (saline) — no significant differences
  • 24–48 h opioid consumption: comparable
  • Pain scores at 24, 48, 72 h: similar across all arms
  • Authors' conclusion: single-shot four-quadrant TAP with LB, plain bupivacaine, or normal saline produced similar postoperative opioid consumption and pain scores

This is the trial that questions the value of pre-incision single-shot TAP blocks altogether — not just LB specifically.

EXPLANE 2022[10]​

Multicenter RCT (n = 498), LB TAP vs continuous epidural for major abdominal surgery:

  • Pain at rest: TAP non-inferior to epidural (difference 0.09 points; p < 0.05 for non-inferiority)
  • Less hypotension with TAP (31% vs 48%)
  • Slightly more opioid with TAP (+21 mg over 3 days)
  • Important for cystectomy / major-reconstruction patients who are often volume-depleted post-op

Hussain 2024 Anesthesiology meta[11]​

Abdominal fascial-plane blocks, LB vs plain local anesthetics: primary outcome (AUC pain 24–72 h) not different (SMD −0.21; p = 0.058). Robust to COI- and mixing-with-plain-bupivacaine subgroup. Authors: does not support evidence-based preference for LB.

Evidence — Urologic Surgery Specifically​

Radical cystectomy with diversion​

StudyDesignFinding
Chu 2021 (retrospective cohort)LB infiltration vs epidural at fascial closureLB: shorter LOS (4.9 vs 5.9 d); less opioid; lower cost. Confounded by epidural-related hypotension and immobility[12]
Schmidt 2021 (prospective comparison)LB infiltration vs standard bupivacaine infiltrationNo difference in PACU opioid (9.0 vs 6.5 MED; p = 0.29), hospital opioid (36.8 vs 42.1 MED; p = 0.81), POD 1/2/3 pain scores, or LOS (5.0 vs 4.9 d). Authors: "no significant difference"[13]

The combined reading: LB appears "better than epidural" in retrospective cystectomy data largely because it avoids epidural-associated hypotension and immobility — not because the liposomal formulation is pharmacologically superior to standard bupivacaine. When compared head-to-head with standard bupivacaine, there is no difference.

Laparoscopic / robotic urologic surgery​

Knight 2015 RCT (n = 206): LB vs 0.25% bupivacaine — no difference in total opioid (15 vs 17.3 mg MME; p = 0.39), pain scores, LOS, or time to first opioid. "No significant difference between liposomal bupivacaine and 0.25% bupivacaine."[14]

Surgeon-administered TAP in cystectomy​

Roebuck 2022 (n = 178) — not LB-specific, but documents that any TAP block is associated with lower POD 0–3 opioid use (106.4 vs 192.2 MME; p = 0.004) and shorter LOS (5.6 vs 7.7 d) — again reinforcing that the block location matters more than the specific formulation.[15]

Quality of Recovery — The Most Favorable Signal​

Zhang 2025 meta (11 RCTs, n = 1,357) — the strongest positive evidence for LB, focused on patient-centered recovery outcomes:[18]

  • Quality of Recovery (QoR) at 72 h: SMD 0.52 (95% CI 0.20–0.85; p = 0.00)
  • ↓ pain scores at 24, 48, 72 h
  • ↓ cumulative opioid within 72 h
  • ↓ PONV
  • ↑ patient satisfaction

Interpretation: the analgesic advantage on traditional pain scales is small-to-none, but the overall recovery experience may be improved. Weigh against cost and the industry-bias concerns in the broader literature.

Cost​

AgentCost per vial
Liposomal bupivacaine (Exparel)~$300–400 (20 mL, 266 mg)
Standard bupivacaine HCl~$2–5
  • Hamilton 2022 JAMA Surgery (knee replacement) — LB dominated by standard bupivacaine (less effective, more costly); only 37% probability of cost-effectiveness at £20,000/QALY threshold.[17]
  • Babazade 2019 cost-effectiveness analysis — IVPCA was most cost-effective; TAP + LB narrowly dominated; epidural clearly dominated.[16]

The cost differential is difficult to justify given the consistent absence of clinically meaningful superiority over standard bupivacaine across 76+ RCTs.

Safety Profile​

Similar to standard bupivacaine. No unique serious adverse events identified.[4][6]

  • Common (≥ 10%): nausea, constipation, vomiting
  • Cardiovascular toxicity: same risk as all bupivacaine formulations — cardiac arrest, ventricular arrhythmias, collapse. Monitor CV and neurologic status during and after injection.
  • CNS toxicity: restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, convulsions, unconsciousness, respiratory depression
  • Methemoglobinemia with concurrent methemoglobin-inducing agents
  • Hepatic impairment — caution (amide-type, hepatically metabolized)
  • Chondrolysis risk — not approved for intra-articular use
  • Pregnancy — no adequate studies; crosses placenta; use only if benefit justifies risk

For the LAST (Local Anesthetic Systemic Toxicity) framework and 20%-lipid-emulsion rescue protocol, see Local anesthetics.

Evidence Summary​

Clinical questionEvidenceStrength
LB infiltration vs standard bupivacaine infiltrationNo clinically meaningful superiority in 89% of RCTs; ↓ pain 0.37 pts at 24 h (below MCID)Strong — 76+ RCTs, multiple meta-analyses[1][2][5][6]
LB TAP block vs standard bupivacaine TAP vs salineCLEVELAND 2025 — all three equivalentStrong — RCT[9]
LB TAP vs epiduralNon-inferior pain; less hypotension (31% vs 48%); slightly more opioidModerate — EXPLANE RCT[10]
LB in radical cystectomyLB infiltration superior to epidural (retrospective confounding); LB = standard bupivacaine head-to-headLow–moderate[12][13]
LB in laparoscopic / robotic urologyNo benefit over standard bupivacaineModerate — Knight 2015 RCT[14]
Cost-effectivenessDominated in knee replacement; narrowly dominated by IVPCA for abdominal surgeryModerate[16][17]
Financial COI14× more likely to report positive pain outcomesStrong — SR[2]
Quality of recoveryModest advantage in patient-centered measuresModerate — 2025 meta[18]

Practical Pearls​

  • The preponderance of evidence does not support routine use of liposomal bupivacaine over standard bupivacaine in wound infiltration or TAP for reconstructive / urologic surgery. Across 76+ RCTs, only 11% demonstrated clinically relevant benefit.[1][5]
  • Financial COI is a major interpretive concern — industry-affiliated studies are 14× more likely to report positive pain outcomes.[2]
  • CLEVELAND 2025 is the trial to know. Saline TAP, plain bupivacaine TAP, and LB TAP all produced identical outcomes — the trial questions the value of pre-incision single-shot TAP blocks regardless of formulation.[9]
  • In radical cystectomy-with-diversion, LB infiltration appears better than epidural in retrospective data (probably a hypotension / immobility confounder) but is not different from standard bupivacaine head-to-head.[12][13]
  • LB TAP may be a reasonable alternative when epidural is contraindicated — EXPLANE showed non-inferior pain with significantly less hypotension (31% vs 48%), clinically relevant in volume-depleted cystectomy patients.[10]
  • Preparation rules matter. Lidocaine admixture (or within 20 min of LB at the same site) destroys the sustained-release mechanism. Hypotonic dilution disrupts liposomal particles. Use a ≥ 25-gauge needle and NS or LR only.[4]
  • 96-hour "do-not-give-additional-local-anesthetics" rule is a unique constraint that limits multimodal pain-management flexibility at the same site.[4]
  • Cost is prohibitive — ~$300–400/vial vs $2–5 for standard bupivacaine. Cost-effectiveness analyses routinely find LB dominated or only marginally cost-effective.[16][17]
  • Quality-of-recovery data (2025) are the most favorable signal for LB — worth knowing about, but should be weighed against the broader evidence base and industry-bias concerns.[18]
  • Local anesthetics — parent class hub covering 12 urologic use cases, LAST protocol, standard bupivacaine / lidocaine / ropivacaine dosing
  • NSAIDs & analgesics — opioid-sparing multimodal context
  • ERAS — enhanced-recovery protocol in which TAP blocks and wound infiltration sit
  • Postoperative constipation & ileus — the downstream benefit of opioid-sparing analgesia

References​

1. Ilfeld BM, Eisenach JC, Gabriel RA. "Clinical effectiveness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain." Anesthesiology. 2021;134(2):283–344. doi:10.1097/ALN.0000000000003630

2. Ji YD, Harris JA, Gibson LE, McKinley SK, Phitayakorn R. "The efficacy of liposomal bupivacaine for opioid and pain reduction: a systematic review of randomized clinical trials." J Surg Res. 2021;264:510–533. doi:10.1016/j.jss.2021.02.024

3. Prabhakar A, Ward CT, Watson M, et al. "Liposomal bupivacaine and novel local anesthetic formulations." Best Pract Res Clin Anaesthesiol. 2019;33(4):425–432. doi:10.1016/j.bpa.2019.07.012

4. US Food and Drug Administration. EXPAREL (bupivacaine liposome injectable suspension) — prescribing information. Updated 2025-12-12.

5. Dinges HC, Wiesmann T, Otremba B, et al. "The analgesic efficacy of liposomal bupivacaine compared with bupivacaine hydrochloride for the prevention of postoperative pain: a systematic review and meta-analysis with trial sequential analysis." Reg Anesth Pain Med. 2021;46(6):490–498. doi:10.1136/rapm-2020-102427

6. Hamilton TW, Athanassoglou V, Mellon S, et al. "Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain." Cochrane Database Syst Rev. 2017;2:CD011419. doi:10.1002/14651858.CD011419.pub2

7. Sandhu HK, Miller CC, Tanaka A, Estrera AL, Charlton-Ouw KM. "Effectiveness of standard local anesthetic bupivacaine and liposomal bupivacaine for postoperative pain control in patients undergoing truncal incisions: a randomized clinical trial." JAMA Netw Open. 2021;4(3):e210753. doi:10.1001/jamanetworkopen.2021.0753

8. Saad Sayed M, Rath S, Rasool W, et al. "Efficacy of liposomal bupivacaine versus standard bupivacaine following abdominal surgeries: a systematic review and meta-analysis of randomized controlled trials." Pain Pract. 2025;25(5):e70048. doi:10.1111/papr.70048

9. Turan A, Esa WAS, Brooker J, et al. "Liposomal bupivacaine, plain bupivacaine, and saline for transversus abdominis plane blocks: the CLEVELAND randomized trial." Anesthesiology. 2025. doi:10.1097/ALN.0000000000005869

10. Turan A, Cohen B, Elsharkawy H, et al. "Transversus abdominis plane block with liposomal bupivacaine versus continuous epidural analgesia for major abdominal surgery: the EXPLANE randomized trial." J Clin Anesth. 2022;77:110640. doi:10.1016/j.jclinane.2021.110640

11. Hussain N, Speer J, Abdallah FW. "Analgesic effectiveness of liposomal bupivacaine versus plain local anesthetics for abdominal fascial plane blocks: a systematic review and meta-analysis of randomized trials." Anesthesiology. 2024;140(5):906–919. doi:10.1097/ALN.0000000000004932

12. Chu CE, Law L, Zuniga K, et al. "Liposomal bupivacaine decreases postoperative length of stay and opioid use in patients undergoing radical cystectomy." Urology. 2021;149:168–173. doi:10.1016/j.urology.2020.11.036

13. Schmidt B, Bhambhvani HP, Greenberg DR, et al. "Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: does formulation matter?" Urol Oncol. 2021;39(6):369.e1–369.e8. doi:10.1016/j.urolonc.2020.11.008

14. Knight RB, Walker PW, Keegan KA, et al. "A randomized controlled trial for pain control in laparoscopic urologic surgery: 0.25% bupivacaine versus long-acting liposomal bupivacaine." J Endourol. 2015;29(9):1019–1024. doi:10.1089/end.2014.0769

15. Roebuck E, Beano H, Robinson M, et al. "Surgeon-administered transversus abdominis plane (TAP) block is associated with decreased opioid usage and length of stay following radical cystectomy." Urology. 2022;161:135–141. doi:10.1016/j.urology.2021.11.023

16. Babazade R, Saasouh W, Naylor AJ, et al. "The cost-effectiveness of epidural, patient-controlled intravenous opioid analgesia, or transversus abdominis plane infiltration with liposomal bupivacaine for postoperative pain management." J Clin Anesth. 2019;53:56–63. doi:10.1016/j.jclinane.2018.10.003

17. Hamilton TW, Knight R, Stokes JR, et al. "Efficacy of liposomal bupivacaine and bupivacaine hydrochloride vs bupivacaine hydrochloride alone as a periarticular anesthetic for patients undergoing knee replacement: a randomized clinical trial." JAMA Surg. 2022;157(6):481–489. doi:10.1001/jamasurg.2022.0713

18. Zhang L, Yang S, Liu X, et al. "Impact of liposomal bupivacaine on subjective recovery quality after surgery: a meta-analysis of randomized controlled trials." Front Med. 2025;12:1655756. doi:10.3389/fmed.2025.1655756